Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 3.91% to $10.08 on Tuesday, underperforming competitors like Vanda Pharmaceuticals and Fortress Biotech. The decline ended a five-day winning streak and occurred amid broader market weakness, with the NASDAQ Composite down 1.33%. Trading volume was below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) shed 3.91% to $10.08 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index falling 1.33% to 26,289.71 and Dow Jones Industrial Average falling 0.22% to 53,343.40.
The stock's fall snapped a five-day winning streak.
Corbus Pharmaceuticals Holdings Inc. closed 50.97% short of its 52-week high of $20.56, which the company reached on October 20th.
The stock underperformed when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc. (VNDA) rose 3.42% to $5.44, Fortress Biotech Inc. (FBIO) rose 3.19% to $2.91, and Viking Therapeutics Inc. (VKTX) fell 0.77% to $33.37.
Trading volume (329,116) remained 54,139 below its 50-day average volume of 383,255.
Data source: Dow Jones Market Data, FactSet. Data compiled August 18, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-18-26 1721ET